SHL – Morgan Stanley rates the stock as Overweight

Morgan Stanley increases earnings estimates, expecting benefits from ongoing coronavirus testing and a recovery in base business volumes.

For now, the broker assumes testing ends in December 2021 with a minimal contribution from US serology testing in 2022. Morgan Stanley believes the strength of the balance sheet is under appreciated by the market. Covid-19 testing has also driven gearing to record lows.

The broker retains an Overweight rating and raises the target to $39.80 from $39.70. Industry view: In-line.

Sector: Health Care Equipment & Services.


Target price is $39.80.Current Price is $35.21. Difference: $4.59 – (brackets indicate current price is over target). If SHL meets the Morgan Stanley target it will return approximately 12% (excluding dividends, fees and charges – negative figures indicate an expected loss).



Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →